The Saudi Food and Drug Authority (SFDA) is the authority that oversees all drug manufacturing, trade and registration in Saudi Arabia.
Saudi Arabian guidelines for generics
Home/Guidelines
|
Posted 01/07/2011
0
Post your comment
The SFDA is in charge of licensing the manufacture, import, export, distribution, promotion and advertising of medications, as well as assessing the safety, efficacy and quality of medications, and issuing marketing authorisations.
The SFDA also carries out inspections and surveillance of manufacturers, importers, wholesalers and dispensers of medicines; controls promotion and advertising of medicines; and provides independent information on medicines to professionals and the public.
Overarching guidelines
These guidelines cover all generic products:
Guidelines for pharmaceutical equivalence requirements version 1.1
1 September 2010
www.sfda.gov.sa/NR/rdonlyres/C6CC3730-5B8C-4E82-A261-5EEBC71F3D01/0/PharmaceuticalEquivalence_v11.pdf
Bioequivalence guidelines
These guidelines are specifically related to bioequivalence studies for generic products:
The GCC guidelines for bioequivalence version 2
Issue date: 3 February 2011
Implementation date: 3 May 2011
www.sfda.gov.sa/NR/rdonlyres/8369AD75-FD1B-4F57-9253-65FD062AF666/0/TheGCCGuidelinesforBioequivalence_2011.pdf
Related article
Saudi Arabian guidelines for biosimilars
Source: SFDA
Policies & Legislation
ANVISA and DINAVISA sign MoU to strengthen border surveillance and regulatory cooperation
Congress pushes biosimilar bills as interchangeability concerns linger
Reports
Central America moves toward joint evaluation of biosimilar medicines
The US$52 billion question: can the US keep biosimilars competitive?
Most viewed articles
The best selling biotechnology drugs of 2008: the next biosimilars targets
Global biosimilars guideline development – EGA’s perspective
Related content
Brazil's ANVISA updates guidance on pharmacokinetic studies for biosimilars
Canada eliminates phase III trial requirement for biosimilar approvals
FDA updates draft biosimilar guidance, signalling greater flexibility for developers
FDA finalizes Guidance on Promotional Labeling and Advertising for biologicals
Related content
Brazil's ANVISA updates guidance on pharmacokinetic studies for biosimilars
Home/Guidelines Posted 20/08/2026
Canada eliminates phase III trial requirement for biosimilar approvals
Home/Guidelines Posted 22/06/2026
FDA updates draft biosimilar guidance, signalling greater flexibility for developers
Home/Guidelines Posted 12/06/2026
FDA finalizes Guidance on Promotional Labeling and Advertising for biologicals
Home/Guidelines Posted 25/05/2026
Most viewed articles
The best selling biotechnology drugs of 2008: the next biosimilars targets
Post your comment